Heart failure with preserved ejection fraction based on aging and comorbidities

被引：0
作者：
Ying Lin
Shihui Fu
Yao Yao
Yulong Li
Yali Zhao
Leiming Luo
机构：
[1] Hainan Hospital of Chinese People’s Liberation Army General Hospital,Department of Cardiology
[2] Chinese People’s Liberation Army General Hospital,Department of Geriatric Cardiology
[3] Medical School of Duke University,Centre for the Study of Ageing and Human Development and Geriatrics Division
[4] National School of Development,Centre for Healthy Ageing and Development Studies
[5] Peking University,Central Laboratory
[6] Hainan Hospital of Chinese People’s Liberation Army General Hospital,undefined
来源：
Journal of Translational Medicine | / 19卷
关键词：
Aging; Comorbidities; Diagnosis; Heart failure with preserved ejection fraction; Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Heart failure (HF) with preserved ejection fraction (HFpEF) is a leading cause of hospitalizations and mortality when diagnosed at the age of ≥ 65 years. HFpEF represents multifactorial and multisystemic syndrome and has different pathophysiology and phenotypes. Its diagnosis is difficult to be established based on left ventricular ejection fraction and may benefit from individually tailored approaches, underlying age-related changes and frequent comorbidities. Compared with the rapid development in the treatment of heart failure with reduced ejection fraction, HFpEF presents a great challenge and needs to be addressed considering the failure of HF drugs to improve its outcomes. Further extensive studies on the relationships between HFpEF, aging, and comorbidities in carefully phenotyped HFpEF subgroups may help understand the biology, diagnosis, and treatment of HFpEF. The current review summarized the diagnostic and therapeutic development of HFpEF based on the complex relationships between aging, comorbidities, and HFpEF.
引用
收藏
相关论文
共 377 条
  • [71] Rich MW(2001)The pathogenesis of acute pulmonary edema associated with hypertension N Engl J Med 344 17-1865
  • [72] Kitzman DW(2018)Catheter ablation for atrial fbrillation with heart failure N Engl J Med 378 417-732
  • [73] Upadhya B(2016)Atrial fibrillation in heart failure with preserved ejection fraction: association with exercise capacity, left ventricular filling pressures, natriuretic peptides, and left atrial volume JACC Heart Fail 5 92-133
  • [74] Haykowsky MJ(2019)Atrial fbrillation ablation strategies and outcome in patients with heart failure: insights from the German ablation registry Clin Res Cardiol 108 815-773
  • [75] Eggebeen J(2013)Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction J Am Coll Cardiol 62 1857-88
  • [76] Kitzman DW(2008)Anemia and heart failure: a community study Am J Med 121 726-1150
  • [77] Ather S(2018)Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-defcient heart failure patients: an individual patient data meta-analysis Eur J Heart Fail 20 125-2033
  • [78] Murad K(2016)The infuence of iron defciency on the functioning of skeletal muscles: experimental evidence and clinical implications Eur J Heart Fail 18 762-2467
  • [79] Kitzman D(2003)Angiotensin AT1/AT2 receptors: regulation, signalling and function Blood Press 12 70-580
  • [80] Franssen C(2017)Regulation and functions of the renin–angiotensin system in white and brown adipose tissue Compr Physiol 7 1137-1186
3456789101112